US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CV Sciences, Inc.

0.0305

+0.00155.17%

Volume:1.83M

Turnover:61.52K

Market Cap:5.90M

PE:-5.87

High:0.0371

Open:0.0298

Low:0.0290

Close:0.0290

52wk High:0.1000

52wk Low:0.0230

Shares:193.46M

Float Shares:184.26M

Volume Ratio:1.75

T/O Rate:0.99%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0052

EPS(LYR):0.0201

ROE:-58.72%

ROA:-3.95%

PB:4.02

PE(LYR):1.51

Loading ...

Overview Company News Filings

CV Sciences announces annual shareholder meeting

CV Sciences cuts note conversion price to $0.03 in debt amendment

CV Sciences Q4 sales fall

CV Sciences FY2025 operating loss narrows to $0.5 million; revenue drops 12.2% to $13.8 million on lower sales volume

Cv Sciences Q4 Pretax Profit USD -204 Thousand

THOMSON REUTERS

CV Sciences to release full-year and Q4 2025 results and host investor conference call

CV Sciences adds $0.06-per-share conversion feature to outstanding notes in debt restructuring

CV Sciences Reports Third Quarter Revenue of $3.3 Million

Cv Sciences Q3 Pretax Profit USD -382 Thousand

THOMSON REUTERS

CV Sciences Inc. to Release Third Quarter 2025 Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CVSI/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CVSI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CVSI\",,,,,undefined,":{"symbol":"CVSI","market":"US","secType":"STK","nameCN":"CV Sciences, Inc.","latestPrice":0.0305,"timestamp":1776456000000,"preClose":0.029,"halted":0,"volume":1825517,"delay":15,"changeRate":0.051724137931034406,"floatShares":184263663,"shares":193458420,"eps":-0.005199,"marketStatus":"Market Closed","change":0.0015,"latestTime":"04-17 16:00:00 EDT Delay","open":0.0298,"high":0.0371,"low":0.029,"amount":61516.805850000004,"amplitude":0.27931,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.005199,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1776672000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"OTCQB","adjPreClose":0.029,"volumeRatio":1.7518022136170004},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CVSI\",,,,,undefined,":{"symbol":"CVSI","floatShares":184263663,"roa":"-3.95%","roe":"-58.72%","lyrEps":0.020148,"volumeRatio":1.7518022136170004,"shares":193458420,"dividePrice":0,"high":0.0371,"amplitude":0.27931,"preClose":0.029,"low":0.029,"week52Low":0.023,"pbRate":"4.02","psRate":"0.43","week52High":0.1,"institutionHeld":0,"latestPrice":0.0305,"eps":-0.005199,"divideRate":0,"volume":1825517,"delay":15,"ttmEps":-0.005199,"open":0.0298,"prevYearClose":0.0614,"prevWeekClose":0.0361,"prevMonthClose":0.0325,"prevQuarterClose":0.0325,"fiveDayClose":0.0361,"twentyDayClose":0.035,"sixtyDayClose":0.044},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CVSI\",params:#limit:5,,,undefined,":[{"date":"2026-03-26","symbol":"CVSI","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774555200000,"name":null,"time":"Post Market","dateTimestamp":1774497600000,"actualEps":null},{"date":"2025-11-13","symbol":"CVSI","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1763067600000,"name":null,"time":"Post Market","dateTimestamp":1763010000000,"actualEps":null},{"date":"2025-08-13","symbol":"CVSI","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755115200000,"name":null,"time":"Post Market","dateTimestamp":1755057600000,"actualEps":null},{"date":"2025-05-14","symbol":"CVSI","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1747252800000,"name":null,"time":"Post Market","dateTimestamp":1747195200000,"actualEps":null},{"market":"US","date":"2025-03-27","symbol":"CVSI","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CVSI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CVSI\",market:\"US\",delay:true,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CVSI\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2627867283","title":"CV Sciences announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2627867283","media":"Reuters","labels":["shareholding","conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627867283?lang=en_us&edition=fundamental","pubTime":"2026-04-15 18:11","pubTimestamp":1776247886,"startTime":"0","endTime":"0","summary":"CV Sciences scheduled annual shareholder meeting for June 2, 2026 in virtual format.Shareholders will vote to elect three directors, including Jamie Corroon, Joseph Dowling, Bill McCorkle.Ballot includes authorization for reverse stock split ranging from 1-for-10 to 1-for-800, with board discretion to set final ratio by May 30, 2029.Meeting agenda includes ratification of Haskell & White as independent registered public accounting firm for fiscal 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CV Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 15, 2026, and is sol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL1ftfLt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","CVSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626110429","title":"CV Sciences cuts note conversion price to $0.03 in debt amendment","url":"https://stock-news.laohu8.com/highlight/detail?id=2626110429","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626110429?lang=en_us&edition=fundamental","pubTime":"2026-04-11 04:04","pubTimestamp":1775851485,"startTime":"0","endTime":"0","summary":"CV Sciences amended terms of its secured convertible notes, resetting fixed conversion price to USD 0.03 per share.Company issued a new senior secured convertible note on April 6, 2026 with principal amount USD 99,614.Amendment extended maturity of that note to July 6, 2027.Conversion price for new note was fixed at USD 0.03 per share, based on a lesser-of formula tied to prior-day closing price.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CV Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 10, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDLlCRXy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","CVSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622896238","title":"CV Sciences Q4 sales fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2622896238","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622896238?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:10","pubTimestamp":1774555858,"startTime":"0","endTime":"0","summary":"CV Sciences Q4 sales fallOverviewU.S. hemp extracts seller's Q4 sales declined yr/yr due to lower volumes and regulatory challengesCompany posted positive adjusted EBITDA in Q4, driven by reduced oper","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nL1N40E14R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVSI","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622896439","title":"CV Sciences FY2025 operating loss narrows to $0.5 million; revenue drops 12.2% to $13.8 million on lower sales volume","url":"https://stock-news.laohu8.com/highlight/detail?id=2622896439","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622896439?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:08","pubTimestamp":1774555714,"startTime":"0","endTime":"0","summary":"CV Sciences filed a Form 8-K reporting full-year and fourth-quarter 2025 results.Revenue was USD 13.8 million, down 12.2%, and gross margin was 49.0%, up 3.4 percentage points.Operating loss was USD 0.5 million, and adjusted EBITDA loss was USD 0.3 million.Cash was USD 300,000 at year-end, down 40%, while operating expenses fell 17.2% to USD 7.7 million .Management attributed the revenue decline to lower sales volume tied to temporary out-of-stock issues for key products and restrictive regulations at the federal level and in certain states, and CEO Joseph Dowling said the company is focused on operating efficiency, consistent positive cash flow, and disciplined acquisitions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CV Sciences I","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL24d2GJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","CVSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622896398","title":"Cv Sciences Q4 Pretax Profit USD -204 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2622896398","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622896398?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:00","pubTimestamp":1774555201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nPLXBC5DE5:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4183","CVSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622015928","title":"CV Sciences to release full-year and Q4 2025 results and host investor conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2622015928","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622015928?lang=en_us&edition=fundamental","pubTime":"2026-03-25 05:00","pubTimestamp":1774386033,"startTime":"0","endTime":"0","summary":"CV Sciences will release financial results for the year ended December 31, 2025 after the stock market closes on March 26, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL8KfHBf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVSI","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618469961","title":"CV Sciences adds $0.06-per-share conversion feature to outstanding notes in debt restructuring","url":"https://stock-news.laohu8.com/highlight/detail?id=2618469961","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618469961?lang=en_us&edition=fundamental","pubTime":"2026-03-11 05:00","pubTimestamp":1773176423,"startTime":"0","endTime":"0","summary":"CV Sciences modified its outstanding notes to add a conversion feature allowing note balances to be converted into common shares at a fixed price of USD 0.06 per share.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDL9scTvF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVSI","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2583116235","title":"CV Sciences Reports Third Quarter Revenue of $3.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583116235","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583116235?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:00","pubTimestamp":1763067626,"startTime":"0","endTime":"0","summary":"CV Sciences Inc. reported revenue of $3.3 million for the third quarter of 2025, down from $3.9 million in the same period of 2024 and $3.6 million in the second quarter of 2025. Gross margin was 48.5% for the third quarter of 2025, compared to 46.0% in the third quarter of 2024 and 50.9% in the previous quarter. The company ended the quarter with a cash balance of $0.4 million, compared to $0.5 million at the end of 2024. Adjusted EBITDA showed a loss of $0.1 million for the third quarter of 2025, compared to a loss of $0.1 million in the same period last year and a positive $0.1 million in the previous quarter. During the quarter, CV Sciences expanded its product offering with the launch of Ignite, a men's performance formula.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL4rcy4X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVSI","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2583611511","title":"Cv Sciences Q3 Pretax Profit USD -382 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2583611511","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583611511?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:00","pubTimestamp":1763067601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLX1D52FB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4183","CVSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2582957389","title":"CV Sciences Inc. to Release Third Quarter 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2582957389","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582957389?lang=en_us&edition=fundamental","pubTime":"2025-11-11 07:15","pubTimestamp":1762816556,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CV Sciences Inc. published the original content used to generate this news brief via ACCESS Newswire  on November 10, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL80BVnG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","CVSI"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}]}}